Calidi Biotherapeutics, Inc.
NYSE · Healthcare · Biological Products, (No Diagnostic Substances) · San Diego, CA
CLDI chart
What traders are saying about $CLDI
Latest postsCalidi Biotherapeutics, Inc. news
- Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE Biofactories
Yahoo Finance ·
- Calidi Biotherapeutics, Inc. Estimates – AMEX:CLDI
TradingView ·
- Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026
Yahoo Finance ·
- Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency
Yahoo Finance ·
- Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
Yahoo Finance ·
- Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance ·
- Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Yahoo Finance ·
- Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference
Yahoo Finance ·
- Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers
Yahoo Finance ·
- Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
Yahoo Finance ·
- Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
Yahoo Finance ·
- Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit
Yahoo Finance ·
Calidi Biotherapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | – | $45,000 |
| Net income | -$19.9M | -$22.1M | -$29.2M | -$25.4M |
| Diluted EPS | $-5.95 | $-35.70 | $-17.33 | $2.99 |
| Total assets (year end) | $8.9M | $14.2M | $10.0M | $2.6M |
| Cash and equivalents (year end) | – | $9.6M | – | – |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Calidi Biotherapeutics, Inc.
- Ticker
- CLDI (NYSE)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- San Diego, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1855485
- Former names
- Calidi Biotherapeutics, Inc., First Light Acquisition Group, Inc.
Frequently asked questions
What exchange is Calidi Biotherapeutics, Inc. listed on?
Calidi Biotherapeutics, Inc. trades on the NYSE under the ticker symbol CLDI.
What industry is Calidi Biotherapeutics, Inc. in?
Calidi Biotherapeutics, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Calidi Biotherapeutics, Inc. headquartered?
Calidi Biotherapeutics, Inc.'s business address on file with the SEC is in San Diego, CA.
When does Calidi Biotherapeutics, Inc.'s fiscal year end?
Calidi Biotherapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Calidi Biotherapeutics, Inc. report?
Calidi Biotherapeutics, Inc. reported $45,000 in revenue for calendar year 2022, according to its SEC filings.